Kasuki Leandro, Rocha Paula da Silva, Lamback Elisa Baranski, Gadelha Mônica Roberto
Centro de Pesquisa em Neuroendocrinologia, Divisão de Endocrinologia, Faculdade de Medicina e Hospital Universitário Clementino Fraga Filho, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.
Serviço de Neuroendocrinologia, Instituto Estadual do Cérebro Paulo Niemeyer, Rio de Janeiro, RJ, Brasil.
Arch Endocrinol Metab. 2019 Nov-Dec;63(6):630-637. doi: 10.20945/2359-3997000000193.
Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown a change in the severity and prevalence of these complications. In addition, acromegaly is associated with increased mortality, but recent studies (especially those published in the last decade) have shown a different scenario than older studies, with mortality no longer being increased in adequately controlled patients and a change in the main cause of death from cardiovascular disease to malignancy. In this review, we discuss this changing face of acromegaly summarizing current knowledge and evidence on morbimortality of the disease. Arch Endocrinol Metab. 2019;63(6):630-7.
肢端肥大症是一种与发病率增加相关的全身性疾病,会出现心血管、代谢、呼吸、肿瘤、内分泌、关节和骨骼并发症。通过适当的疾病治疗,这些合并症大多可以预防或延缓,并且最近关于肢端肥大症现代治疗方法的研究表明,这些并发症的严重程度和患病率有所变化。此外,肢端肥大症与死亡率增加相关,但最近的研究(尤其是过去十年发表的研究)呈现出与早期研究不同的情况,在病情得到充分控制的患者中死亡率不再增加,主要死因也从心血管疾病转变为恶性肿瘤。在本综述中,我们讨论肢端肥大症这一不断变化的面貌,总结有关该疾病发病率和死亡率的现有知识及证据。《巴西内分泌与代谢杂志》。2019年;63(6):630 - 637。